Recent news on Tracleer

Actelion sees positive results in CTEPH as boost for Tracleer  -  May 24, 2007
Pharma Times (subscription),Actelion, the Swiss pharmaceutical company, is upbeat this week on news that its dual endothelin receptor antagonist Tracleer (bosentan) significantly

Encysive Pharmaceuticals "reduce," estimates reduced  -  May 16, 2007
newratings.com...which would show Ambrisentan to be safe and effective in patients who have discontinued Actelion’s Tracleer or Thelin due to liver toxicity,

Annual General Meeting of Shareholders in Basel, Switzerland  -  May 4, 2007
PharmaLive.com (press release),Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension

No Earnings At Encysive  -  May 8, 2007
Motley FoolThis is a solid piece of market share that Thelin has carved out against Actelion's Tracleer so soon in this patient group, and improves the outlook for

Actelion announces first quarter results 2007  -  Apr 19, 2007
PharmaLive.com (press release),We grew Tracleer® in the marketplace. We demonstrated the benefits of our dual endothelin receptor antagonist in patients suffering from

Actelion Q1 Net Loss 150 Mln Sfr, Raises Outlook  -  Apr 19, 2007
Reuters.uk,Sales of pulmonary arterial hypertension drug Tracleer -- which makes up almost all of Actelion's sales -- rose to 260.4 million francs compared to 201.4

Actelion Q1 net swings to 150 mln sfr loss vs 53.7 mln profit ...  -  Apr 18, 2007
ABCmoney.co.uk,During the first quarter of 2007, net revenue increases 38 pct year-on-year to 290.4 mln sfr, with key product pulmonary arterial hypertension drug Tracleer

Gilead's Atripla, Lower Costs Provide Lift To First Quarter  -  Apr 22, 2007
BioWorld Online,Actelion already had Tracleer (bosentan) for PAH. "They're really different classes, though, and I don't think I'd look at the second drug [Ventavis] as

Viagra has given me chance to stay alive  -  Apr 21, 2007
Scotsman,The hospital arranged for him to go to Glasgow, where he was treated at Gartnavel Royal Hospital and they put him on Tracleer tablets to bring down his

Bosentan (Tracleer) receives positive EU opinion for reduction of ...  -  27 Mar 2007
PharmaLive.com (press release),The CHMP has recommended that the European Commission approve bosentan (Tracleer®) for the reduction of the number of new digital ulcers in patients with

Actelion says European Medicines Agency recommends further ...  -  Mar 25, 2007
Forbes,ZURICH (AFX) - Actelion said that the Committee for Medicinal Products for Human Use has recommended that the European Commission approve Tracleer for the

Positive Study with Bosentan (Tracleer) in CTEPH  -  Mar 5, 2007
PharmaLive.com (press release),The study met its primary objective, as treatment with bosentan (Tracleer) was associated with a significant reduction in pulmonary vascular resistance PVR

Committee for Medicinal Products for Human Use Post-authorisation ...  -  Mar 23, 2007
PharmaLive.com (press release),..."Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease (see section

Actelion's pulmonary hypertension drug Tracleer study meets ...  -  Mar 4, 2007
ABCmoney.co.uk,Patients on Tracleer showed a significant improvement in breathlessness with exercise, the Swiss pharma group said. Initial results also indicated that

EU Panel Backs Wider Use of Roche, Actelion Drugs  -  Mar 23, 2007
Reuters.uk,It also backed the use of Actelion's Tracleer for reducing the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer

Celgene's thalidomide-derived Revlimid gets European nod  -  Mar 26, 2007
Pharma Times (subscription),Tracleer (bosentan) to include reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Swiss shares flat as rising oil prices offset tentative Wall St gains  -  Mar 26, 2007
ABCmoney.co.uk,...after the pharma group said that the Committee for Medicinal Products for Human Use has recommended that the European Commission approve Tracleer for

Meeting Highlights From The Committee For Medicinal Products For ...  -  Mar 23, 2007
Medical News Today (press release),Tracleer (bosentan), from Actelion Registration Ltd, to extend the indication to include reduction of the number of new digital ulcers in patients with

Encysive's Outback Adventures  -  Mar 7, 2007
Motley FoolFor example, Encysive's biggest competitor, Actelion (with its PAH treatment, Tracleer) brought in $760 million in revenue last year.

Actelion "overweight," target price raised  -  Feb 26, 2007
newratings.comPAH and Zavesca businesses and the multi-billion dollar potential of the company’s four products, Tracleer, orexin-RA, renin inhibitor and S1P1.

Swiss shares continue sharply lower in-line with US futures  -  Mar 5, 2007
ABCmoney.co.uk,Outside the SMI, focus was on Actelion, 6 sfr or 2.3 pct at 25, after the pharma group said a study of key drug Tracleer as treatment for inoperable forms

Swiss shares sharply down tracking Wall Street, Asian falls  -  Mar 5, 2007
ABCmoney.co.uk,Outside the SMI, focus was on Actelion, 3.50 sfr or 1.3 pct at 259.50, ahead of the SPI after the pharma group said a study of key drung Tracleer as

European bourses decline from a six-year high  -  25 Feb 2007
Gulf Times,The Swiss biotechnology company that makes the Tracleer lung treatment said operating income probably will be as much as 75mn Swiss francs this year,

Actelion Announces Full Year 2006 Financial Results  -  Feb 21, 2007
Primenewswire (press release),I expect that Tracleer(r), Ventavis(r) and Zavesca(r) will continue to grow in the coming years, as the result of the favorable characteristics each

Actelion net profit 241 mln Sfr, beats forecasts  -  Feb 21, 2007
ReutersS: Quote, Profile, Research) nearly doubled to 241 million Swiss francs ($194.7 million) on strong sales of its key drug Tracleer, beating forecasts.

Net income almost doubles at Switzerland's Actelion  -  Feb 22, 2007
Pharma Times (subscription),Switzerland's Actelion says that earnings almost doubled in 2006 thanks to strong sales of its pulmonary artery hypertension product Tracleer.

Actelion FY net beats forecasts on healthy sales growth  -  Feb 21, 2007
Forbes,The Swiss pharmaceuticals firm cited strong product sales, with sales of its key anti-pulmonary arterial hypertension drug Tracleer up 42 pct at 898.7 mln

Pharmacopeia tout 2-for-1 cardiovascular drug  -  Feb 19, 2007
DrugResearcher.com,Tracleer (bosentan) is an example of a drug that binds to both receptors. It is marketed by Actelion Pharmaceuticals as a treatment for pulmonary arterial

Actelion shares down, rival gets priority review  -  Feb 19, 2007
Therapeutics Daily (subscription) (press release),...fell on Monday after Gilead's ambrisentan, a potential rival to the Swiss company's key hypertension drug Tracleer, was granted US priority review.

Panacos Appoints Dr. Tom Lategan, Vice President of Regulatory Affairs  -  Feb 14, 2007
Business Wire (press release),While at Actelion, Dr. Lategan compiled and submitted the successful New Drug Application (NDA) for TRACLEER in the US and Canada, and managed subsequent

European Stocks Decline From a Six-Year High; Clariant Drops  -  Feb 24, 2007
BloombergThe Swiss biotechnology company that makes the Tracleer lung treatment said operating income probably will be as much as 75 million Swiss francs this year,

Panacos Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 21, 2007
Business Wire (press release),Dr. Lategan was instrumental in the regulatory approvals of several drugs, including TRACLEER, ZAVESCA, and ANGIOMAX and was previously Vice President,

Actelion Announces Full Year 2006 Financial Results  -  Feb 22, 2007
PharmaLive.com (press release),I expect that Tracleer®, Ventavis® and Zavesca® will continue to grow in the coming years, as the result of the favorable characteristics each medication

Gilead Closes the Gap  -  Feb 21, 2007
Motley FoolActelion has proven that there is a large and growing market for endothelin receptor antagonists, raking in Tracleer sales in excess of $550 million in just

Successful Proof-of-Concept With Actelion's Orexin Receptor ...  -  Feb 4, 2007
Primenewswire (press release),Actelion's first drug Tracleer(r), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial

European Stocks Advance, Led by EADS, Daimler on M&A Outlook  -  Feb 19, 2007
BloombergActelion Ltd. retreated 4.9 percent to 294.25 francs after US regulators speeded up a review of a rival product to Tracleer, the Swiss biotechnology

European Stocks Advance, Led by EADS, Daimler on M&A Outlook  -  Feb 19, 2007
BloombergActelion Ltd. retreated 4 percent to 297 francs after US regulators speeded up a review of a rival product to Tracleer, the Swiss biotechnology company's

Actelion calls its Zero Coupon Convertible Bond 2003-2008  -  18 Jan 2007
PharmaLive.com (press release),Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension

Successful study with Tracleer(R) in patients with mildly ...  -  Jan 15, 2007
CNW Telbec (Communiqués de presse),The study met its main secondary endpoint, as treatment with Tracleer(R) was associated with a significant delay in time to clinical worsening compared to

Successful Study with Tracleer in Patients with Mildly Symptomatic ...  -  Jan 15, 2007
PharmaLive.com (press release),Treatment with Tracleer(R) in 185 mildly symptomatic PAH patients (NYHA modified functional class II) was associated with a highly significant reduction in

Actelion initiated with "sell"  -  Jan 17, 2007
newratings.comIn a research note published yesterday, the analyst mentions that the company’s leading drug Tracleer is expected to face stiff competition from Gilead’s

Switzerland's Actelion seals acquisition of CoTherix  -  Jan 9, 2007
Pharma Times (subscription),It currently has Tracleer (bosentan) which had sales of over $500 million in the first nine months of 2006 and will now be getting hold of CoTherix'

On the Move: Suez, Nokia, ABN Amro  -  Dec 29, 2006
BusinessWeekPharmaceuticals' (ENCY) experimental drug Thelin for an often fatal lung condition, likely giving a competitive advantage to the company's Tracleer.

Encysive Drops on FDA Delay  -  Dec 29, 2006
TheStreet.comSeveral drugs are already available, including market-leader Tracleer from Actelion and Revatio, a Pfizer (PFE - commentary - Cramer's Take) drug that

Successful Study With Tracleer in Patients With Mildly Symptomatic ...  -  Dec 18, 2006
PharmaLive.com (press release),Treatment with Tracleer(r) in 185 mildly symptomatic PAH patients (NYHA modified functional class II) was associated with a highly significant reduction in

Actelion Says Study Shows Positive Tracleer Results  -  Dec 18, 2006
Therapeutics Daily (subscription) (press release),ZURICH (Reuters) - Actelion said on Monday it would look to file its Tracleer drug for use in earlier-stage patients after positive study results,

Actelion reports positive Tracleer study results for light ...  -  Dec 17, 2006
Forbes,ALLSCHWIL, Switzerland (AFX) - Actelion Ltd announced positive results from a Phase IIIb study of its Tracleer drug in patients with a light,

Drugs from Gilead/GlaxoSmithKline and Encysive Will Challenge ...  -  Dec 5, 2006
Drug Newswire (press release),Ambrisentan and Encysive's Thelin will challenge Actelion's Tracleer for market leadership in the treatment of pulmonary arterial hypertension (PAH).

Actelion "overweight," target price raised  -  Dec 19, 2006
newratings.comIn a research note published this morning, the analyst mentions that the EARLY study indicates that Tracleer provides clinical benefits to PAH patients who

Europe: Mixed trade after recent gains  -  Dec 18, 2006
ShareCast,News of positive results from a study of its lung drug Tracleer had drugmaker Actelion moving ahead, but Sanofi-Aventis dropped on worries about its Ketek

Actelion Ltd. Announces Commencement of Cash Tender Offer for ...  -  Dec 8, 2006
PharmaLive.com (press release),Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension

The Best Small Cap for 2007: Encysive Pharmaceuticals  -  Dec 7, 2006
Motley FoolAfter more than five years on the market in both the EU and US, Actelion's Tracleer has ramped up sales to more than $500 million in just the first nine

Combo Therapy Superior for Pulmonary Arterial Hypertension  -  Dec 1, 2006
MedPage Today,1 -- Combining Ventavis (iloprost) with Tracleer (bosentan) may improve clinical and functional outcomes in pulmonary arterial hypertension, according to a

Zacks Analyst Interview Highlights: Pfizer, CoTherix and Gilead ...  -  Dec 5, 2006
Business Wire (press release),Actelion, also a big player in PAH with market leading oral drug, Tracleer, was interested in getting their hands on this data registry,

Actelion CoTherix Acquisition Seen Sensible  -  Nov 30, 2006
newratings.comHowever, "we keep our rating at reduce based on the strong run of the shares within the last months, our fundamental valuation of the stock and Tracleer

European Stocks Fall for First Time in Two Weeks, Led by BP  -  Dec 18, 2006
BloombergActelion Ltd. climbed 3.6 percent to 253 Swiss francs after the company said a study showed its best-selling lung drug Tracleer helps patients who suffer

Swiss shares close slightly higher amid lower oil prices UPDATE  -  Dec 18, 2006
Forbes,Outside the SMI, Actelion climbed 9.70 sfr or 4 pct to 254.00, profiting from positive results from a Phase IIIb study of its Tracleer drug in patients with

European Energy Stocks Advance, Led by Statoil; BT Declines  -  Dec 18, 2006
BloombergActelion Ltd. climbed 4.6 percent to 255.5 Swiss francs after the drugmaker said a study showed its best-selling lung drug Tracleer helps patients who

European Markets Fall On Weak Oils - European Commentary  -  Dec 18, 2006
Trading Markets,Actelion Ltd. surged up 3.6% after the company said a study showed its best-selling lung drug Tracleer helps patients who suffer from an early form of

Swiss shares higher in afternoon on falling oil prices, positive ...  -  Dec 18, 2006
Forbes,Outside the SMI, Actelion climbed 7.70 sfr to 3.2 pct to 252.00, profiting from positive results from a Phase IIIb study of its Tracleer drug in patients

Euroshares flat midday; Statoil, Norsk Hydro up on oil & gas merger  -  Dec 18, 2006
Forbes,Actelion added 2.95 pct after it announced positive results from a Phase IIIb study of its Tracleer drug in patients with a light, symptomatic form of

European Energy Stocks Advance, Led by Statoil; BT Declines  -  Dec 18, 2006
BloombergActelion Ltd. climbed 3 percent to 251.5 Swiss francs after the drugmaker said a study showed its best-selling lung drug Tracleer helps patients who suffer

Euroshares open flat; Statoil, Norsk Hydro up on oil & gas merger ...  -  Dec 18, 2006
Forbes,Actelion added 4.18 pct after it announced positive results from a Phase IIIb study of its Tracleer drug in patients with a light, symptomatic form of

European Energy Stocks Advance, Led by Statoil; BT Declines  -  Dec 18, 2006
BloombergActelion Ltd. climbed 3.9 percent to 253.75 Swiss francs after the drugmaker said a study showed its best-selling lung drug Tracleer helps patients who

Swiss shares slightly higher in thin morning trade helped by Wall ...  -  Dec 18, 2006
Forbes,Outside the SMI, Actelion climbed 2.3 pct or 5.95 sfr to 250.25, profiting from positive results from a Phase IIIb study of its Tracleer drug in patients

European Stocks Have Best Week Since July on M&A Speculation  -  Dec 16, 2006
Bloomberg...after the company announced it was beginning late-phase trials of a new lung treatment that may reduce the dependence on its best-selling Tracleer drug.

Communications Media Promotes Darren Martino  -  Dec 12, 2006
PharmaLive.com (press release),Darren currently has planning responsibilities for Lustra, Topicort, U-Kera-E, Ovide, Tracleer, Aptivus and Viramune. Please join me in congratulating

Encysive receives FDA clearance for drug trial  -  Dec 9, 2006
Bizjournals.com,Gilead Sciences Inc.'s (NASDAQ:GILD) ambrisentan and Actelion's Tracleer, and an expected dilutive financing will remain an overhang on ENCY shares."

(PRN) - Xtreme Graphics Launches New INFINIDEPTH(TM) Drinkware ... [+]  -  Dec 5, 2006
Bolsamania.com,...(PRN) - Drugs from Gilead/GlaxoSmithKline and Encysive Will Challenge Actelion's Tracleer for Market Leadership in the Treatment of Pulmonary Arterial

CHEST: Idiopathic Pulmonary Fibrosis Responds to Tracleer  Oct 27, 2006
Note that this study suggests some idiopathic pulmonary fibrosis patients may derive a limited benefit from treatment with Tracleer (bosentan) although the ... -MedPage Today, Actelion 9-mths results beat forecasts on continued strong ...  Oct 18, 2006
...profit reaching 171.8 mln sfr, up from 101.3 mln a year ago, driven by continued strong sales growth of its key pulmonary arterial hypertension drug Tracleer. ... -Forbes, Actelion Announces 9-Month Results for 2006  Oct 18, 2006
In the market place, we have been very successful in increasing awareness about PAH and the unprecedented treatment option provided by Tracleer(r), our dual ... -PrimeZone (press release), Actelion to continue clinical trial of Clazosentan  Oct 9, 2006
Clazosentan is Actelion's most-advanced drug candidate, and the June setback came at a time when Actelion's only marketed product, Tracleer, has started to see ... -MarketWatch Kepler Raises Actelion's Target Price  Oct 20, 2006
..."In our September 1 report, we highlighted that the Tracleer franchise for pulmonary arterial hypertension alone was worth CHF195 per share. ... -newratings.com Goldman Raises Actelion's Target To CHF302  Oct 20, 2006
Jones] Goldman Sachs raises Actelion's (ATLN.EB) target price to CHF302 from CHF254, to account for an increase in projected growth rates for Tracleer and the ... -newratings.com WestLB Lowers Actelion To Reduce From Hold  Oct 23, 2006
Also, with a positive view of penetrating the pulmonary arterial hypertension market, and competition to Actelion's flagship Tracleer, WestLB arrives at a fair ... -newratings.com Encysive's Tempting Prospects  Nov 3, 2006
Germany represent about 40% of its market in Europe, which will equate to something north of $200 million, considering that competing drug Tracleer did $500 ... -Motley Fool EARNINGS PREVIEW: Actelion 3Q Net Pft Seen +25%  Oct 13, 2006
The increase is driven by strong demand for its lead product, Tracleer. Sales are seen +34% to CHF243.1M from CHF180.8M. Analysts ... -newratings.com New Drug Fights Common Disease Among Premenopausal Women  Oct 9, 2006
There's a relatively new drug that turned out to be a magic bullet for her though: tracleer. ... Tracleer doesn't work for all of them. ... -Pittsburgh Channel.com, 2nd UPDATE: Actelion 3Q Net +89%; Raises '06 Guidance  Oct 19, 2006
...company Actelion Ltd (ATLN.EB) Thursday reported a 89% rise in net profit during the third quarter, fueled by strong sales of flagship drug Tracleer. ... -Therapeutics Daily (subscription) (press release), European Stocks May Slide, Led by Infineon; Novartis May Rise  Oct 18, 2006
Actelion Ltd. may be active. The Swiss biotechnology company said third-quarter earnings rose 30 percent, helped by sales of its Tracleer lung treatment. ... -Bloomberg Swiss shares lower on mixed US closing, profit-taking; Nestle top ...  Oct 19, 2006
...months results, with net profit of 171.8 mln sfr, above an expected 155.0 mln sfr thanks to strong sales growth of its key pulmonary hypertension drug Tracleer ... -Forbes, Actelion Announces Nine Month Results for 2006  Oct 19, 2006
In the market place, we have been very successful in increasing awareness about PAH and the unprecedented treatment option provided by Tracleer®, our dual ... -PharmaLive.com (press release), Committee for Medicinal Products for Human Use Post-authorisation ...  Sep 22, 2006
...positive opinion?? to recommend the variation to the terms of the marketing authorisation for the medicinal product Tracleer. The ... -PharmaLive.com

First and Only Treatment Option Approved for Pulmonary Arterial ...  Sep 7, 2006
TORONTO, CANADA -- September 7, 2006 -- Tracleer® (bosentan) is now indicated by Health Canada for the treatment of pulmonary arterial hypertension (PAH) in ... -DG News

New PAH Drug Devt Helpful For Actelion  Sep 15, 2006
The clinical trials are being done in combination with Actelion's Tracleer, and thus "it could provide additional upside for our Tracleer forecasts as ... -newratings.com

First and only treatment option approved for pulmonary arterial ...  Sep 7, 2006
7 /CNW Telbec/ - Tracleer(R) (bosentan) is now indicated by Health Canada for the treatment of pulmonary arterial hypertension (PAH) in patients with PAH ... -Canada NewsWire

CHMP Posts Positive Opinion On Eli Lilly's Byetta  Sep 21, 2006
Tracleer (bosentan), from Actelion Registration Ltd, received a positive opinion to extend the indication to pulmonary arterial hypertension patients ... -Easy Bourse (Communiqués de presse)

Biogen Idec Licenses PAH Drug From MondoBiotech  Sep 14, 2006
The current PAH market includes approved drugs such as Tracleer (bosentan, Actelion Ltd.) and Revatio (sildenafil, Pfizer Inc.). ... -BioWorld Online

Exercise and Respiratory Training Ease Life With Pulmonary ...  Sep 19, 2006
Baseline drug therapy included Tracleer (bosentan), Revatio (sildenafil), Ventavis (iloprost), Flolan (epoprostenol), beraprost, and calcium channel blockers. ... -MedPage Today

Credit Suisse Ups Actelion Target To CHF210  Sep 12, 2006
...sales growth prospects. Raises revenue estimates for main drug, Tracleer, which treats pulmonary arterial hypertension. Says the ... -newratings.com

FOCUS: Product Chain To Spur Interest In Biovitrum IPO  Sep 5, 2006
Swiss Actelion (ATLN.EB), which has been on the stock market since 2000, has seen its share rise 52% year-to-date as its main drug Tracleer, a treatment for ... -Easy Bourse (Communiqués de presse)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional